Nephron Pharmaceuticals Investing $313 Million in SC Expansion Expected to Create 707 Jobs
10/28/2011
Nephron is a global leader in manufacturing generic respiratory medications available to retail pharmacies, hospitals, home care companies and other customers. Its Orlando, Florida-based headquarters is comprised of 250,000-sq.-ft. of manufacturing, distribution and packaging facilities. The company has distribution centers in Kentucky and Arizona.
"We are excited to expand our company by locating our new manufacturing facility in Lexington County" said CEO Lou Kennedy. "This is a big step for our firm and will help us meet increased demand, expand our market share and develop our pipeline of products. South Carolina has an excellent business environment and we look forward to our expansion into the Palmetto State."
The South Carolina Dept. of Commerce has committed a set-aside grant of $4.5 million for site preparation and infrastructure. Nephron also was approved for job development credits, available when hiring targets are met. In addition, it will receive training support from the state's ReadySC program.
Project Announcements
GE Appliances Expands Jefferson County, Kentucky, Operations
06/30/2025
ValorFlex Packaging Plans Bowling Green, Kentucky, Production Operations
06/30/2025
Neuro.io Plans Terrebonne Parish, Louisiana, Operations
06/30/2025
Germany-Based MTU Maintenance Expands Fort Worth, Texas, MRO Operations
06/30/2025
Cascade Die Casting Group Expands High Point, North Carolina, Manufacturing Operations
06/30/2025
BuildOps Plans Raleigh, North Carolina, Operations
06/30/2025
Most Read
-
20th Annual Area Development Gold and Silver Shovel Awards
Q2 2025
-
First Person: Joe Capes, CEO, LiquidStack
Q2 2025
-
The Legal Limits of DEI in Incentives Agreements, Hiring, and Contracting
Q2 2025
-
From Silicon to Server: Mapping the Data Center Supply Chain
Q2 2025
-
39th Annual Corporate & 21st Annual Consultants Surveys: What Business Leaders and Consultants Are Saying About Site Selection
Q1 2025
-
Rethinking Life Sciences Site Selection in a Resilient and Dynamic Market
Q2 2025
-
Top States for Doing Business in 2024: A Continued Legacy of Excellence
Q3 2024